Neoadjuvant Nivolumab (NIVO) + Platinum-Doublet Chemotherapy (chemo) Versus Chemo for Resectable (IB–IIIA) Non-Small Cell Lung Cancer (NSCLC): Association of Pathological Regression with Event-Free Survival (EFS) in CheckMate 816.
Journal of Clinical Oncology(2022)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要